This Fact Sheet is provided by Lexaria Bioscience Corporation as a convenience for potential investors. More details about the business and its risks can be found in the Company’s press releases and filings with the U.S. Securities and Exchange Commission or the Canadian Securities Administrators. This Fact Sheet contains forward-looking statements and actual results may differ materially from such statements. www.lexariabioscience.com February 2020 Lexaria Bioscience Corp. CSE:LXX | OTCQX:LXRP Lexaria Bioscience has developed a new disruptive drug delivery platform: DehydraTECH™ The Company’s patented technology changes the way Active Pharmaceutical Ingredients (“APIs”) enter the body orally: 1) Masks unwanted tastes – eliminates the need for sugar-filled edibles. 2) Reduces time of onset – effects are felt within 10-20 min vs. 60-120 min. 3) Avoids first-pass liver metabolism – mitigating unwanted side effects. 4) Increases bio-absorption up to 5-10X - to equate absorption by inhalational delivery. The Company’s DehydraTECH™ technology is patent-protected for multiple APIs: Cannabidiol (CBD), Tetrahydrocannabinol (THC), Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, Nicotine, Fat soluble vitamins. Business Model: 1) Out-license (royalty) the technology to third-party partners / distributors. 2) Product Sales - Lexaria sells hemp oil CBD ( cannabidiol ) products. ViPova™ branded premium teas deliver CBD in several flavors. TurboCBD™ hemp oil capsules are formulated with Ginseng & Ginkgo for enhanced focus and memory. ChrgD + ™ hemp oil infused dissolvable powder for use in any beverage. Growing Patent Portfolio – 16 patents granted, and over 60 patent applications pending worldwide. Patents include both method and composition of matter claims. Increasing number of DehydraTECH™ licensees for cannabis, such as: 1906 New Highs and Hill Street Beverage Company. Lexaria Nicotine - A majority-owned subsidiary of Lexaria Bioscience, utilizing DehydraTECH™ to develop oral nicotine delivery forms in partnership with a one of the world’s largest producers and marketers of nicotine products. Lab testing has demonstrated that DehydraTECH™ improves oral nicotine delivery, enabling healthier nicotine delivery formats. For more information, contact Chris Bunka, CEO: (250) 765-6424, Email: [email protected] Stock Information: Trading symbol: CSE:LXX, OTCQX:LXRP Shares o/s: 80m, (f/d: 90m) Mgmt & Insiders: 18m (22.5%) Key Executives: Chris Bunka - Chairman & CEO Serial entrepreneur, extensive experience in the capital markets, corporate governance, M&A and finance. John Docherty, M.Sc. - Director & President 20 yr. senior executive in the pharmaceutical and bioscience M.Sc. in pharmacology and B.Sc. in toxicology from the University of Toronto. Dr. Edward Ergenzinger – Chief Legal Advisor, Innovation Advisor U.S. licensed patent attorney, Doctorate in Neuroscience (with concentrations in Pharmacology and Physiology). Dr. Philip Ainslie – Advisor Co-Director for the Centre for Heart, Lung and Vascular Health, Canada, Faculty of Health and Social Development at the University of BC.